Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Ref Type | |||||||||||||
PMID | |||||||||||||
Authors | Hendrik-Tobias Arkenau, Joaquin Mateo, Charlotte Rose Lemech, Jeffrey R. Infante, Howard A. Burris, Yung-Jue Bang, Joseph Paul Eder, Roy S. Herbst, Sunil Sharma, Hyun Cheol Chung, Shaun Decordova, Karen E Swales, Michelle D Garrett, Jill I Loftiss, Michae | ||||||||||||
Title | A phase I/II, first-in-human dose-escalation study of GSK2636771 in patients (pts) with PTEN-deficient advanced tumors. | ||||||||||||
|
|||||||||||||
URL | http://meetinglibrary.asco.org/content/131727-144 | ||||||||||||
Abstract Text | J Clin Oncol 32:5s, 2014 (suppl; abstr 2514) |
Molecular Profile | Treatment Approach |
---|
Gene Name | Source | Synonyms | Protein Domains | Gene Description | Gene Role |
---|
Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
---|
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|
Gene | Variant | Impact | Protein Effect | Variant Description | Associated with drug Resistance |
---|
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
PTEN dec exp | Advanced Solid Tumor | sensitive | GSK2636771 | Phase Ib/II | Actionable | In a Phase I/II trial, GSK2636771 treatment inhibited Akt signaling, and resulted in partial response in 2% (1/53) and stable disease in 25% (13/53) of patients with PTEN-deficient advanced solid tumors (J Clin Oncol 32:5s, 2014 (suppl; abstr 2514)). | detail... |